Organ Preservation Solution Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Organ Type (Heart, Lung, Kidney, Liver, Others), By Application (Static Cold Storage, Hypothermic Machine Perfusion, Normothermic Machine Perfusion, Others), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 281.24 Million
CAGR (2026-2031)	6.92%
Fastest Growing Segment	University of Wisconsin Solution (UW Solution)
Largest Market	North America
Market Size (2031)	USD 420.06 Million

Market Overview

The Global Organ Preservation Solution Market will grow from USD 281.24 Million in 2025 to USD 420.06 Million by 2031 at a 6.92% CAGR. Organ preservation solutions are specialized pharmacological formulations designed to maintain cellular viability and minimize ischemic injury in donor organs during the interval between procurement and transplantation. The global market is primarily driven by the increasing prevalence of end-stage organ failure necessitated by chronic diseases and an aging population, which heightens the fundamental demand for transplant procedures. Additionally, the expansion of organ donation networks and improved logistical capabilities for transporting organs over longer distances support the sustained consumption of these preservation media as healthcare systems strive to maximize graft survival rates.

However, the persistent disparity between the high demand for organs and the limited supply of available donors remains a significant challenge restricting market potential. According to the Global Observatory on Donation and Transplantation, in 2024, it was reported that 172,397 solid organ transplants were performed globally over the preceding year. This statistic underscores that while transplant activity is robust, the scarcity of viable organs inherently limits the total addressable volume for preservation solutions, thereby impeding broader market expansion.

Key Market Drivers

Technological advancements in organ preservation and perfusion are fundamentally reshaping the market by extending the viability of donor organs and enabling the utilization of marginal grafts. The industry is witnessing a significant transition from static cold storage to dynamic machine perfusion systems, which maintain organs in a metabolically active state during transport. This shift not only improves post-transplant outcomes but also drastically expands the donor pool by making organs from Donors After Circulatory Death (DCD) more viable for successful transplantation. The impact of these technologies on donor utilization is evident in recent national data; according to the Health Resources and Services Administration (HRSA), January 2025, in the '2024 Organ Donation and Transplantation Data', the number of DCD donors in the United States increased by 23.5% in 2024 compared to the previous year, a surge directly supported by improved clinical preservation capabilities.

Simultaneously, the rising global volume of organ transplantation procedures serves as a primary catalyst for the sustained consumption of preservation solutions. As healthcare infrastructure improves and international donor networks become more efficient, the aggregate number of surgeries requiring pharmacological preservation media has intensified. According to the United Network for Organ Sharing (UNOS), January 2025, in the '2024 Annual Transplant Statistics', the United States achieved a historic milestone with 48,149 transplants performed in 2024, reflecting a 3.3% growth over the prior year. Despite this increase in procedural volume, the prevalence of chronic organ failure continues to outpace the supply of viable organs, creating persistent market demand for solutions that maximize graft survival; for instance, according to NHS Blood and Transplant, November 2025, in the 'Current UK Statistics', there are currently 8,237 patients on the active transplant waiting list in the United Kingdom, underscoring the critical reliance on effective preservation to optimize every available donation.

Download Free Sample Report

Key Market Challenges

The scarcity of viable donor organs acts as a primary constraint on the commercial volume of the organ preservation solution market. Since these pharmacological products are essential consumables utilized strictly during the retrieval and transport phases of transplantation, their market consumption is inextricably linked to the number of available grafts. Consequently, the revenue potential for manufacturers is capped by the supply of donor organs rather than the actual clinical demand from patients suffering from end-stage organ failure. When the availability of organs stagnates, the procurement volume of preservation media inevitably faces a ceiling, regardless of the prevalence of disease.

This supply-demand imbalance creates a persistent bottleneck that restricts the total addressable market. According to the Organ Procurement and Transplantation Network, as of January 2024, there were more than 103,000 candidates registered on the national transplant waiting list in the United States. This substantial disparity between the high number of patients awaiting procedures and the limited inventory of donor organs prevents the industry from scaling in proportion to patient needs. The gap ensures that despite the critical necessity for life-saving procedures, the sales volume for preservation solutions remains restricted to the finite number of donations realized annually.

Key Market Trends

The integration of IoT and real-time organ viability monitoring is establishing a new standard in the market by converting passive storage units into intelligent, data-driven devices. This trend focuses on safeguarding donor grafts through app-native ecosystems that continuously track critical parameters such as temperature and location, thereby mitigating risks associated with unmonitored transport. The clinical impact of this technology is substantial; according to Paragonix Technologies, April 2024, in the 'GUARDIAN-Heart Clinical Registry' report, the utilization of their advanced preservation system with real-time monitoring capabilities resulted in a 43% reduction in 2-year mortality rates compared to historical ice storage.

Concurrently, the advancement of ex-vivo organ rehabilitation and therapeutics is fundamentally altering preservation strategies by enabling active graft repair and significantly prolonged storage times. Beyond mere maintenance, these therapeutic perfusion protocols allow for the reconditioning of marginal organs and offer unprecedented flexibility in transplant scheduling, moving procedures from emergency settings to planned operations. Highlighting this capability, according to XVIVO Perfusion, January 2024, in a press release regarding a 'Lancet' publication, their hypothermic oxygenated perfusion technology successfully extended total donor liver preservation time up to 20 hours, achieving 100% patient and graft survival at the one-year mark.

Segmental Insights

The University of Wisconsin (UW) Solution segment is identified as the fastest-growing category in the Global Organ Preservation Solution Market, driven by its status as the gold standard for static cold storage. This rapid expansion is fueled by the solution's superior capability to minimize cellular swelling and ischemic injury, extending preservation times for critical organs such as the liver, kidney, and pancreas. Leading transplant institutions prioritize this formulation for its proven clinical efficacy and versatility. Furthermore, consistent regulatory endorsements from bodies like the U.S. Food and Drug Administration reinforce its reliability, sustaining its accelerated adoption in complex transplant procedures globally.

Regional Insights

North America dominates the global organ preservation solution market, driven by a high prevalence of chronic diseases leading to organ failure. The region benefits from a developed healthcare infrastructure and strong government support for transplantation programs. Organizations such as the United Network for Organ Sharing facilitate efficient organ allocation, which sustains the demand for preservation products. Additionally, the presence of established market players and consistent product clearances by the US Food and Drug Administration ensure widespread availability of these solutions, securing North America’s position as the leading regional market.

Recent Developments

• In October 2025, Bridge to Life received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its multi-sourced Belzer UW and MPS organ preservation solutions. This regulatory achievement included expanded labeling for the Belzer MPS solution, authorizing its use across all abdominal organs for flushing and hypothermic machine perfusion. The approval enabled the company to supply a broader range of high-quality preservation media to transplant centers and organ procurement organizations, ensuring greater supply chain stability and supporting the effective preservation of kidneys, livers, and pancreases during critical transplantation procedures.
• In August 2025, TransMedics announced that it had received conditional approval from the U.S. Food and Drug Administration (FDA) for its Investigational Device Exemption to initiate the Next-Generation OCS ENHANCE Heart trial. This substantial clinical study was designed to evaluate the efficacy of the company’s advanced heart preservation technology, specifically aiming to demonstrate the superiority of its perfusion platform over traditional static cold storage in donation after brain death cases. The trial was positioned to support the potential expansion of clinical indications for the device, further solidifying the company’s leadership role in the evolving organ preservation market.
• In November 2024, OrganOx and eGenesis entered into an exclusive clinical co-development agreement to advance a novel liver support system designed for the treatment of acute liver failure. This collaboration aimed to combine OrganOx’s normothermic machine perfusion technology with eGenesis’s human-compatible, genetically engineered porcine livers to facilitate liver recovery or serve as a bridge to transplantation. The companies announced their intention to submit an Investigational New Drug application to regulatory authorities to initiate a Phase 1 clinical study, marking a significant step in research efforts to address the critical shortage of available human donor organs.
• In August 2024, Getinge announced its strategic entry into the global organ preservation and transportation market through the acquisition of Paragonix Technologies. The agreement involved an aggregate purchase price estimated at USD 477 million, comprising upfront and potential earn-out payments. This collaboration was intended to complement Getinge’s existing acute heart and lung support portfolio by integrating Paragonix’s novel organ preservation devices, which utilize stable cooling techniques and digital tracking systems. The acquisition enabled the company to offer comprehensive solutions across the entire transplant workflow, addressing the increasing global demand for donor organs and the shift toward advanced preservation technologies.

Key Market Players

• Paragonix Technologies, Inc.
• XVIVO Perfusion AB
• Dr. Franz Köhler Chemie GmbH
• OrganOx Limited
• Bridge to Life Europe Ltd.
• Waters Medical Systems, LLC
• Preservation Solutions Inc.
• Artivion, Inc.
• Vascular Perfusion Solutions, Inc.
• Global Transplant Solutions

By Organ Type	By Application	By Region
Heart Lung Kidney Liver Others	Static Cold Storage Hypothermic Machine Perfusion Normothermic Machine Perfusion Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Organ Preservation Solution Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Organ Preservation Solution Market, By Organ Type:

• Heart
• Lung
• Kidney
• Liver
• Others

• Organ Preservation Solution Market, By Application:

• Static Cold Storage
• Hypothermic Machine Perfusion
• Normothermic Machine Perfusion
• Others

• Organ Preservation Solution Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE